Poster Tour 02: Pathways to Cure: Advancing Therapeutic Access and Outcomes
Tracks
Track 3
Wednesday, October 15, 2025 |
3:25 PM - 3:50 PM |
Speaker
Doctor Brian Conway
President And Medical Director
Vancouver Infectious Diseases Centre
Safety and efficacy of glecaprevir/pibrentasvir for 8 weeks for people with acute hepatitis C virus infection who use drugs: a sub-analysis of a multicenter, prospective phase 3 study
3:25 PM - 3:30 PMBiography
Dr. Brian Conway, MD, FRCPC, is an infectious diseases specialist. He leads the Vancouver Infectious Diseases Centre, specializing in the design and evaluation of care systems for vulnerable inner-city residents, especially those living with HCV and HIV infection. He has led and published many seminal clinical trials in this field.
Dr Nadhir Adi Azahar
Doctoral Candidate (Public Health)
Universiti Malaya
A QUALITATIVE STUDY EXPLORING BARRIERS AND FACILITATORS TO IMPLEMENTING A RAPID-START DIRECT-ACTING ANTIVIRALS (DAA) MODEL FOR HEPATITIS C TREATMENT AMONG PEOPLE WHO USE DRUGS IN MALAYSIA
3:30 PM - 3:35 PMBiography
Dr. Adi Azahar N, a Doctor of Public Health candidate and trained medical officer, has served in rural Borneo and urban Kuala Lumpur, gaining diverse public health experience. Passionate about harm reduction, infectious diseases, and implementation science, his research focuses on hepatitis C treatment for PWUD and advancing community-based interventions.
Dr. Shilpa Tomar
Scientist C
ICMR-National Institute of Virology, Pune
WHOLE GENOME SEQUENCING AND DRUG RESISTANCE ANALYSIS OF ‘UNUSUAL’ HEPATITIS C SUBTYPES 6XA AND A 3B RELAPSE CASE: A STUDY ON INTRAVENOUS DRUG-USERS ON DIRECT-ACTING ANTIVIRAL (DAA) TREATMENT, INDIA
3:35 PM - 3:40 PMBiography
MBBS, MD Microbiology working as Scientist C in the Hepatitis Group of ICMR-NIV Pune.
Area of reasearch: HCV in intravenous drug users, cardiovascular risk in HCV infection, acute hepatitis of unknown origin (AHUO), CRISPR-based production of knock-out cell lines for HCV
Undertaken outbreak investigations as part of National Central team
Dr Suraj Abdulkarim
Founder
Sufabel Community Development Initiatives
INTEGRATING HIV, HEPATITIS B &C, AND TUBERCULOSIS SERVICES TO IMPROVE HEALTH OUTCOMES AMONG PEOPLE WHO INJECT DRUGS IN GOMBE STATE, NIGERIA
3:40 PM - 3:45 PMBiography
He is a PhD holder with solid background in TB, hepatitis & HIV programme management, health systems analysis, Planning and M&E. Skilled in participatory planning, developing & implementing TB & HIV policies and guidelines. He championed 2005-2009 Gombe State Health Sector Strategic Health Development Plan and HIV/AIDs Anti- Discrimination law
Ms Aristide Mounchili Njifon
Student Phd In Virology
Centre Pasteur Du Cameroun
IDENTIFICATION OF NS5B RESISTANCE-ASSOCIATED MUTATIONS IN HEPATITIS C VIRUS CIRCULATING IN TREATMENT NAÏVE CAMEROONIAN PATIENTS
3:45 PM - 3:50 PMBiography
I'm a young researcher. Passionate about science, I've always been fascinated by how micro-organisms work. I'm committed to scientific research thanks to my initial results, and I've already taken part in national and international workshops and conferences to share my passion for science and encourage others to consider scientific careers.
